Physician profile
Carla Ortique
NPI 1700840105
$757.01
in general payments reported to CMS, 2019-2025
15 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $55.10 · 2021: $85.45 · 2022: $173 · 2023: $33.01 · 2024: $41.29 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $297.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $122.32 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $108.91 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.82 | 2019-2022 | |
| Coopersurgical, INC. | $79.47 | 2019-2024 | Paragard T 380a |
| Hologic Sales and Service, LLC | $67.42 | 2019-2022 | |
| Viiv Healthcare Company | $64.47 | 2025 | |
| Astellas Pharma US INC | $52.49 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $49.65 | 2019-2025 | Slynd |
| Lupin INC. | $30.65 | 2020 | |
| Organon LLC | $26.59 | 2021-2022 | |
| Myovant Sciences INC. | $24.97 | 2022 | |
| Myriad Women'S Health, INC. | $13.31 | 2023 | Myrisk |
| Daiichi Sankyo INC. | $13.16 | 2022 | |
| Merck Sharp & Dohme LLC | $12.50 | 2019 | |
| Allergan, INC. | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Ortique listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.